【摘要】 目的:比较万拉法新与阿米替林治疗糖尿病伴发情绪障碍患者的疗效与安全性。方法:40例伴情绪障碍糖尿病患者,随机分为万拉法新组和阿米替林组,每组各20例。两组患者的疗程均为6周。采用HAMD、HAMA表评定两组患者的临床疗效,TESS表评定患者的不良反应。结果:治疗后1、2周末,万拉法新组患者评分下降较阿米替林组明显,4、6周末差异无显著性;万拉法新组患者的不良反应较阿米替林组少而轻。结论:万拉法新治疗糖尿病伴情绪障碍疗效与阿米替林相当,但起效较快,安全性高,不良反应轻微。更多还原

【Abstract】 Objective: To compare efficacy and safety of Venlafaxine and Amitriptyline in treatment of mood disorders in patients with diabetes mellitus( DM). Methods: 40 patients with DM were randomly assigned to Venlafaxine group and Amitriptyline group and treated for 6 weeks. The efficacy and side reactions were evaluated with Hamilton depression scale( HAMD),Hamilton Anxiety rating scale( HAMA) and treatment emergent symptom scale( TESS). Results: The scores of HAMD and HAMA of Venlafaxine group decreased more markedly than those of Amitriptyline group after the treatment in the first and second weekends. However,there were no significant differences in the 4th and 6th weekends. The side reactions were less and slighter in Venlafaxine group than those in Amitriptyline group. Conclusions: Venlafaxine has a similar efficacy with Amitriptyline in the treatment of the patients with DM,but the former arises faster,the safety is higher,and the side reactions are slighter.更多还原